Custom-Made vaccine targets tumors in Last-Resort patients
NCT ID NCT06963697
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program offers a personalized vaccine made from each patient's unique cancer mutations (neoantigens) to help their immune system fight solid tumors. It is for patients aged 12 and older with local or metastatic cancer who have no other FDA-approved options and a low chance of 5-year survival. The vaccine is given along with an immune booster called poly-ICLC.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Personalized synthetic long peptide vaccine (neoantigen vaccine) plus poly-ICLC adjuvant
What this could lead to
If this vaccine works, it could help control tumor growth by training the immune system to attack cancer cells.
What could go wrong
This is an expanded access program, not a formal trial, so results are not systematically collected. The vaccine is personalized and early-stage, so effectiveness is uncertain and side effects may occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Texas Oncology
AVAILABLEAustin, Texas, 78705, United States
Contact